azithromycin plus hydroxychloroquine in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
0.56 [0.17 ; 1.87 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, ProPAC-COVID, 2021 2 0% 462 moderate not evaluable deaths (time to event analysis only)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
0.64 [0.18 ; 2.24 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
0.99 [0.57 ; 1.72 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 444 NA not evaluable clinical improvementdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
0.81 [0.54 ; 1.22 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 444 NA not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
1.01 [0.58 ; 1.76 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 444 NA not evaluable mechanical ventilationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
1.77 [0.81 ; 3.87 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable ICU admissiondetailed results ProPAC-COVID, 2021 1.24 [0.26; 5.80]
1.24 [0.26 ; 5.80 ] ProPAC-COVID, 2021 1 0% 117 NA not evaluable serious adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
1.87 [0.36 ; 9.75 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
2.22 [1.43 ; 3.44 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
2.24 [0.23 ; 21.69 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
9.79 [1.27 ; 75.50 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 174 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2025-10-31 00:45 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 889
- roots T: 290
